First-in-Human Study of STX-478, a Mutant Selective PI3K alpha Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Primary Objective
This is a first-in-human study to learn more about the investigational drug STX-478. The study will have 3 parts.

Description
Part 1 will study STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will study STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer.
Details
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator

Anthony Elias
Study ID
Protocol Number: 23-0200
More information available at ClinicalTrials.gov: NCT05768139
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers